Document Detail

Improvement of neurocognitive function in responders to an antiviral therapy for chronic hepatitis C.
MedLine Citation:
PMID:  23300053     Owner:  NLM     Status:  MEDLINE    
CONCLUSION: Successful eradication of HCV leads to a significant improvement of relevant aspects of attentional and neurocognitive performance, indicating that the neurocognitive impairment caused by chronic HCV infection is potentially reversible. This therefore suggests an added therapeutic benefit of antiviral treatment in HCV infection. Improvement of neurocognitive function may be an additional treatment indication in patients with HCV. (HEPATOLOGY 2013;58:497-504).
Michael R Kraus; Arne Schäfer; Gerlinde Teuber; Heiner Porst; Kathrin Sprinzl; Sven Wollschläger; Christian Keicher; Michael Scheurlen
Related Documents :
24429103 - Prevention counseling practices of hiv care providers with patients new to hiv medical ...
23304473 - Prevalence of occult hepatitis c virus in egyptian patients with chronic lymphoprolifer...
7604883 - Human immunodeficiency virus-1 gp120 and gp160 envelope proteins modulate mesangial cel...
Publication Detail:
Type:  Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't     Date:  2013-06-24
Journal Detail:
Title:  Hepatology (Baltimore, Md.)     Volume:  58     ISSN:  1527-3350     ISO Abbreviation:  Hepatology     Publication Date:  2013 Aug 
Date Detail:
Created Date:  2013-07-30     Completed Date:  2014-01-16     Revised Date:  2014-08-07    
Medline Journal Info:
Nlm Unique ID:  8302946     Medline TA:  Hepatology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  497-504     Citation Subset:  IM    
Copyright Information:
Copyright © 2013 American Association for the Study of Liver Diseases.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antiviral Agents / therapeutic use*
Attention / drug effects,  physiology
Cognition / drug effects,  physiology
Cognition Disorders / etiology*,  physiopathology*
Drug Therapy, Combination
Follow-Up Studies
Hepatitis C, Chronic / complications*,  drug therapy*
Interferon-alpha / therapeutic use*
Longitudinal Studies
Middle Aged
Polyethylene Glycols / therapeutic use*
Psychological Tests
Recombinant Proteins / therapeutic use
Reproducibility of Results
Ribavirin / therapeutic use*
Treatment Outcome
Reg. No./Substance:
0/Antiviral Agents; 0/Interferon-alpha; 0/Polyethylene Glycols; 0/Recombinant Proteins; 0/peginterferon alfa-2b; 49717AWG6K/Ribavirin
Comment In:
Hepatology. 2014 Jul;60(1):431-2
Hepatology. 2014 Jul;60(1):431   [PMID:  24178628 ]
Hepatology. 2013 Aug;58(2):480-2   [PMID:  23696270 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Enhancing isomaltulose production by recombinant Escherichia coli producing sucrose isomerase: cultu...
Next Document:  Wild Bearded Capuchins Process Cashew Nuts Without Contacting Caustic Compounds.